AGBL3 and rheumatoid arthritis: Notably, this cohort differed from the Healthfair in that pre-RA samples were selected retrospectively from individuals with a known ‘future’ diagnosis of RA and therefore we could not evaluated likelihood of future RA; furthermore, in the DoDSR cohort the earliest or ‘baseline’ visit, an individual did not have to be positive for anti-CCP3.